TY  - JOUR
AU  - Markićević, Milan
AU  - Džodić, Radan R.
AU  - Buta, Marko
AU  - Kanjer, Ksenija
AU  - Mandušić, Vesna
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/203
AB  - Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.
T2  - International Journal of Medical Sciences
T1  - Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up
VL  - 11
IS  - 7
SP  - 663
EP  - 673
DO  - 10.7150/ijms.8194
ER  - 

@article{
author = "Markićević, Milan and Džodić, Radan R. and Buta, Marko and Kanjer, Ksenija and Mandušić, Vesna and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2014",
abstract = "Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.",
journal = "International Journal of Medical Sciences",
title = "Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up",
volume = "11",
number = "7",
pages = "663-673",
doi = "10.7150/ijms.8194"
}

Markićević, M., Džodić, R. R., Buta, M., Kanjer, K., Mandušić, V., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2014). Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up. in International Journal of Medical Sciences, 11(7), 663-673.
https://doi.org/10.7150/ijms.8194

Markićević M, Džodić RR, Buta M, Kanjer K, Mandušić V, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up. in International Journal of Medical Sciences. 2014;11(7):663-673.
doi:10.7150/ijms.8194 .

Markićević, Milan, Džodić, Radan R., Buta, Marko, Kanjer, Ksenija, Mandušić, Vesna, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up" in International Journal of Medical Sciences, 11, no. 7 (2014):663-673,
https://doi.org/10.7150/ijms.8194 . .

TY  - JOUR
AU  - Markićević, Milan
AU  - Kanjer, Ksenija
AU  - Mandušić, Vesna
AU  - Buta, Marko
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5683
AB  - Aim: The aim of this study was to evaluate clinical usefulness of cathepsin D status in early breast cancer during the first 3 years of follow-up. Patients and methods: The study included 226 patients with histologically verified, primary operable invasive early breast carcinomas. Concentrations of estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cytosols were measured by use of the classical biochemical method. The concentration of three cathepsin D forms (52-, 48- and 34-kDa proteins) was determined by a radioimmunoassay Results: On the basis of differences in cathepsin D levels either within an ER-/PR- phenotype or between this and either ER+/PR+ or ER+/PR- phenotypes, a concentration of 39 pmol/mg was determined as the cutoff value for distinguishing estrogen-regulated cathepsin D expression. Estrogen-regulated cathepsin D expression was recognized as a high-risk biomarker for low-risk (histological grade I) breast cancer patients and as a low-risk biomarker for high-risk patients (pN(+) pT2,3). Conclusion: Determination of cathepsin D status in breast cancer might identify patients at different risk for relapse and might facilitate the selection of more or less aggressive adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.
T2  - Biomarkers in Medicine
T1  - Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up
VL  - 7
IS  - 5
SP  - 747
EP  - 758
DO  - 10.2217/bmm.13.62
ER  - 

@article{
author = "Markićević, Milan and Kanjer, Ksenija and Mandušić, Vesna and Buta, Marko and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2013",
abstract = "Aim: The aim of this study was to evaluate clinical usefulness of cathepsin D status in early breast cancer during the first 3 years of follow-up. Patients and methods: The study included 226 patients with histologically verified, primary operable invasive early breast carcinomas. Concentrations of estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cytosols were measured by use of the classical biochemical method. The concentration of three cathepsin D forms (52-, 48- and 34-kDa proteins) was determined by a radioimmunoassay Results: On the basis of differences in cathepsin D levels either within an ER-/PR- phenotype or between this and either ER+/PR+ or ER+/PR- phenotypes, a concentration of 39 pmol/mg was determined as the cutoff value for distinguishing estrogen-regulated cathepsin D expression. Estrogen-regulated cathepsin D expression was recognized as a high-risk biomarker for low-risk (histological grade I) breast cancer patients and as a low-risk biomarker for high-risk patients (pN(+) pT2,3). Conclusion: Determination of cathepsin D status in breast cancer might identify patients at different risk for relapse and might facilitate the selection of more or less aggressive adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.",
journal = "Biomarkers in Medicine",
title = "Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up",
volume = "7",
number = "5",
pages = "747-758",
doi = "10.2217/bmm.13.62"
}

Markićević, M., Kanjer, K., Mandušić, V., Buta, M., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2013). Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up. in Biomarkers in Medicine, 7(5), 747-758.
https://doi.org/10.2217/bmm.13.62

Markićević M, Kanjer K, Mandušić V, Buta M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up. in Biomarkers in Medicine. 2013;7(5):747-758.
doi:10.2217/bmm.13.62 .

Markićević, Milan, Kanjer, Ksenija, Mandušić, Vesna, Buta, Marko, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up" in Biomarkers in Medicine, 7, no. 5 (2013):747-758,
https://doi.org/10.2217/bmm.13.62 . .

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
AU  - Nikolić-Vukosavljević, Dragica
AU  - Nešković-Konstantinović, Zora
AU  - Kanjer, Ksenija
AU  - Hamann, Ute
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5002
AB  - Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
T2  - Cancer Letters
T1  - Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer
VL  - 321
IS  - 1
SP  - 73
EP  - 79
DO  - 10.1016/j.canlet.2012.02.022
ER  - 

@article{
author = "Mandušić, Vesna and Dimitrijević, Bogomir B. and Nikolić-Vukosavljević, Dragica and Nešković-Konstantinović, Zora and Kanjer, Ksenija and Hamann, Ute",
year = "2012",
abstract = "Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.",
journal = "Cancer Letters",
title = "Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer",
volume = "321",
number = "1",
pages = "73-79",
doi = "10.1016/j.canlet.2012.02.022"
}

Mandušić, V., Dimitrijević, B. B., Nikolić-Vukosavljević, D., Nešković-Konstantinović, Z., Kanjer, K.,& Hamann, U.. (2012). Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer. in Cancer Letters, 321(1), 73-79.
https://doi.org/10.1016/j.canlet.2012.02.022

Mandušić V, Dimitrijević BB, Nikolić-Vukosavljević D, Nešković-Konstantinović Z, Kanjer K, Hamann U. Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer. in Cancer Letters. 2012;321(1):73-79.
doi:10.1016/j.canlet.2012.02.022 .

Mandušić, Vesna, Dimitrijević, Bogomir B., Nikolić-Vukosavljević, Dragica, Nešković-Konstantinović, Zora, Kanjer, Ksenija, Hamann, Ute, "Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer" in Cancer Letters, 321, no. 1 (2012):73-79,
https://doi.org/10.1016/j.canlet.2012.02.022 . .

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Popov-Celeketic, Dusan
AU  - Nešković-Konstantinović, Zora
AU  - Kanjer, Ksenija
AU  - Božović, Ana M.
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2010
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4046
AB  - It is well known that breast tumors which are estrogen positive ER(+) are more likely to respond to hormone therapy. However, a certain percentage of ER(+)/PR(+) tumors do not respond to this therapy. Identification of the second estrogen receptor, named estrogen receptor beta (ER), as well as the existence of numerous isoforms/splice variants of both ER alpha and ER beta, suggests that a complex regulation of estrogen action exists. In this study, we analyzed the expression ratio of ER beta 1 isoform and ER beta Delta 5 splice variant mRNAs, and its correlation with ER/PR status by quantitative RT-PCR and clinical and histopathological parameters. We found that the relative proportion of ER beta Delta 5 in the total ER beta 1 transcript pool inversely correlates with the PR level (rho = -0,359, p LT 0,003, Spearman). It may be that the ER beta Delta 5 variant modulates the ERa activity of downstream targets. In addition, we suggest that the determination of the expression profiles of ER alpha and ER beta isoforms and splice variants in the defined groups of patients are necessary for elucidating their involvement in endocrine resistance.
T2  - Archives of Biological Sciences
T1  - Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas
VL  - 62
IS  - 2
SP  - 257
EP  - 262
DO  - 10.2298/ABS1002257M
ER  - 

@article{
author = "Mandušić, Vesna and Popov-Celeketic, Dusan and Nešković-Konstantinović, Zora and Kanjer, Ksenija and Božović, Ana M. and Nikolić-Vukosavljević, Dragica",
year = "2010",
abstract = "It is well known that breast tumors which are estrogen positive ER(+) are more likely to respond to hormone therapy. However, a certain percentage of ER(+)/PR(+) tumors do not respond to this therapy. Identification of the second estrogen receptor, named estrogen receptor beta (ER), as well as the existence of numerous isoforms/splice variants of both ER alpha and ER beta, suggests that a complex regulation of estrogen action exists. In this study, we analyzed the expression ratio of ER beta 1 isoform and ER beta Delta 5 splice variant mRNAs, and its correlation with ER/PR status by quantitative RT-PCR and clinical and histopathological parameters. We found that the relative proportion of ER beta Delta 5 in the total ER beta 1 transcript pool inversely correlates with the PR level (rho = -0,359, p LT 0,003, Spearman). It may be that the ER beta Delta 5 variant modulates the ERa activity of downstream targets. In addition, we suggest that the determination of the expression profiles of ER alpha and ER beta isoforms and splice variants in the defined groups of patients are necessary for elucidating their involvement in endocrine resistance.",
journal = "Archives of Biological Sciences",
title = "Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas",
volume = "62",
number = "2",
pages = "257-262",
doi = "10.2298/ABS1002257M"
}

Mandušić, V., Popov-Celeketic, D., Nešković-Konstantinović, Z., Kanjer, K., Božović, A. M.,& Nikolić-Vukosavljević, D.. (2010). Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas. in Archives of Biological Sciences, 62(2), 257-262.
https://doi.org/10.2298/ABS1002257M

Mandušić V, Popov-Celeketic D, Nešković-Konstantinović Z, Kanjer K, Božović AM, Nikolić-Vukosavljević D. Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas. in Archives of Biological Sciences. 2010;62(2):257-262.
doi:10.2298/ABS1002257M .

Mandušić, Vesna, Popov-Celeketic, Dusan, Nešković-Konstantinović, Zora, Kanjer, Ksenija, Božović, Ana M., Nikolić-Vukosavljević, Dragica, "Levels of Estrogen Receptor B Splice Variant (Erb Delta 5) Mrna Correlates with Progesterone Receptor in Breast Carcinomas" in Archives of Biological Sciences, 62, no. 2 (2010):257-262,
https://doi.org/10.2298/ABS1002257M . .

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Nikolić-Vukosavljević, Dragica
AU  - Tanić, Nikola
AU  - Kanjer, Ksenija
AU  - Nešković-Konstantinović, Zora
AU  - Celeketic, Dusica
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2576
AB  - Purpose In addition to Estrogen Receptor alpha (ER alpha) and Progesterone Receptor (PR), the Second Estrogen Receptor (ER beta) appears to play an important role not only in estrogen signaling, but also in the pathogenesis of cancer in estrogen dependent tissues. The existence of various isoforms and splice variants of both ERs additionally complicates elucidation of their physiological role and involvement in the process of carcinogenesis. Methods In this study, the expression of ER beta 1 mRNA (wild type of beta receptor) and splice variant ER beta Delta 5 mRNA (which codes for truncated protein) was measured by the quantitative RT-PCR (q RT-PCR) in the 60 samples of Breast Cancer (BC) and correlated with ER alpha and PR protein levels and with clinical and histopathological parameters. Results We found the inverse correlation of ER beta Delta 5 mRNA expression with the levels of PR and ER alpha proteins in the group of postmenopausal patients; we also report the lower expression of ER beta 1 and ER beta Delta 5 mRNA in the larger tumors ( GT 20 mm, T2, and T3) than in smaller ones ( LT = 20 mm, T1). The decrease of ER beta Delta 5 mRNA expression in larger tumors is found to arise from ER-positive breast carcinomas. In addition, the portion of tumors with concomitant high expression of both transcripts matches up the known percentage of tumors resistant to endocrine therapy in patients with different ER/PR status. Conclusions As far as we know, this is the first study in which ER beta Delta 5 mRNA splice variant was quantified by realtime RT-PCR in the clinical samples of breast cancer tissue. Until now, the focus of clinical reports was the level of ER beta 1, ER beta 2, and ER beta 5 isoforms. The higher expression of ER beta Delta 5 mRNA is associated with the indicators of low biological aggressiveness of tumor (low tumor size within ER-positive status in our study) suggesting that the uncontrolled local tumor growth may occur as the expression of ER beta Delta 5 mRNA decreases in estrogen-dependent breast cancer.
T2  - Journal of Cancer Research and Clinical Oncology
T1  - Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer
VL  - 133
IS  - 8
SP  - 571
EP  - 579
DO  - 10.1007/s00432-007-0209-x
ER  - 

@article{
author = "Mandušić, Vesna and Nikolić-Vukosavljević, Dragica and Tanić, Nikola and Kanjer, Ksenija and Nešković-Konstantinović, Zora and Celeketic, Dusica and Dimitrijević, Bogomir B.",
year = "2007",
abstract = "Purpose In addition to Estrogen Receptor alpha (ER alpha) and Progesterone Receptor (PR), the Second Estrogen Receptor (ER beta) appears to play an important role not only in estrogen signaling, but also in the pathogenesis of cancer in estrogen dependent tissues. The existence of various isoforms and splice variants of both ERs additionally complicates elucidation of their physiological role and involvement in the process of carcinogenesis. Methods In this study, the expression of ER beta 1 mRNA (wild type of beta receptor) and splice variant ER beta Delta 5 mRNA (which codes for truncated protein) was measured by the quantitative RT-PCR (q RT-PCR) in the 60 samples of Breast Cancer (BC) and correlated with ER alpha and PR protein levels and with clinical and histopathological parameters. Results We found the inverse correlation of ER beta Delta 5 mRNA expression with the levels of PR and ER alpha proteins in the group of postmenopausal patients; we also report the lower expression of ER beta 1 and ER beta Delta 5 mRNA in the larger tumors ( GT 20 mm, T2, and T3) than in smaller ones ( LT = 20 mm, T1). The decrease of ER beta Delta 5 mRNA expression in larger tumors is found to arise from ER-positive breast carcinomas. In addition, the portion of tumors with concomitant high expression of both transcripts matches up the known percentage of tumors resistant to endocrine therapy in patients with different ER/PR status. Conclusions As far as we know, this is the first study in which ER beta Delta 5 mRNA splice variant was quantified by realtime RT-PCR in the clinical samples of breast cancer tissue. Until now, the focus of clinical reports was the level of ER beta 1, ER beta 2, and ER beta 5 isoforms. The higher expression of ER beta Delta 5 mRNA is associated with the indicators of low biological aggressiveness of tumor (low tumor size within ER-positive status in our study) suggesting that the uncontrolled local tumor growth may occur as the expression of ER beta Delta 5 mRNA decreases in estrogen-dependent breast cancer.",
journal = "Journal of Cancer Research and Clinical Oncology",
title = "Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer",
volume = "133",
number = "8",
pages = "571-579",
doi = "10.1007/s00432-007-0209-x"
}

Mandušić, V., Nikolić-Vukosavljević, D., Tanić, N., Kanjer, K., Nešković-Konstantinović, Z., Celeketic, D.,& Dimitrijević, B. B.. (2007). Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer. in Journal of Cancer Research and Clinical Oncology, 133(8), 571-579.
https://doi.org/10.1007/s00432-007-0209-x

Mandušić V, Nikolić-Vukosavljević D, Tanić N, Kanjer K, Nešković-Konstantinović Z, Celeketic D, Dimitrijević BB. Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer. in Journal of Cancer Research and Clinical Oncology. 2007;133(8):571-579.
doi:10.1007/s00432-007-0209-x .

Mandušić, Vesna, Nikolić-Vukosavljević, Dragica, Tanić, Nikola, Kanjer, Ksenija, Nešković-Konstantinović, Zora, Celeketic, Dusica, Dimitrijević, Bogomir B., "Expression of estrogen receptor beta wt isoform (ER beta 1) and ER beta Delta 5 splice variant mRNAs in sporadic breast cancer" in Journal of Cancer Research and Clinical Oncology, 133, no. 8 (2007):571-579,
https://doi.org/10.1007/s00432-007-0209-x . .

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Krtolica-Žikić, Koviljka
AU  - Nikolić-Vukosavljević, Dragica
AU  - Popov-Celeketic, D.
AU  - Plećaš, D.
AU  - Boricic, I.
AU  - Dimitrijević, Bogomir B.
AU  - Tanić, Nikola
PY  - 2007
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3414
T2  - Archives of Biological Sciences
T1  - Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.
VL  - 59
IS  - 2
SP  - 15P
EP  - 16P
DO  - 10.2298/ABS070215PM
ER  - 

@article{
author = "Mandušić, Vesna and Krtolica-Žikić, Koviljka and Nikolić-Vukosavljević, Dragica and Popov-Celeketic, D. and Plećaš, D. and Boricic, I. and Dimitrijević, Bogomir B. and Tanić, Nikola",
year = "2007",
journal = "Archives of Biological Sciences",
title = "Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.",
volume = "59",
number = "2",
pages = "15P-16P",
doi = "10.2298/ABS070215PM"
}

Mandušić, V., Krtolica-Žikić, K., Nikolić-Vukosavljević, D., Popov-Celeketic, D., Plećaš, D., Boricic, I., Dimitrijević, B. B.,& Tanić, N.. (2007). Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.. in Archives of Biological Sciences, 59(2), 15P-16P.
https://doi.org/10.2298/ABS070215PM

Mandušić V, Krtolica-Žikić K, Nikolić-Vukosavljević D, Popov-Celeketic D, Plećaš D, Boricic I, Dimitrijević BB, Tanić N. Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.. in Archives of Biological Sciences. 2007;59(2):15P-16P.
doi:10.2298/ABS070215PM .

Mandušić, Vesna, Krtolica-Žikić, Koviljka, Nikolić-Vukosavljević, Dragica, Popov-Celeketic, D., Plećaš, D., Boricic, I., Dimitrijević, Bogomir B., Tanić, Nikola, "Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues." in Archives of Biological Sciences, 59, no. 2 (2007):15P-16P,
https://doi.org/10.2298/ABS070215PM . .

TY  - CONF
AU  - Nikolić-Vukosavljević, Dragica
AU  - Mandušić, Vesna
AU  - Nešković-Konstantinović, Zora
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3479
C3  - Breast
T1  - Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance
VL  - 16
SP  - S13
EP  - S14
DO  - 10.1016/S0960-9776(07)70069-3
ER  - 

@conference{
author = "Nikolić-Vukosavljević, Dragica and Mandušić, Vesna and Nešković-Konstantinović, Zora and Dimitrijević, Bogomir B.",
year = "2007",
journal = "Breast",
title = "Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance",
volume = "16",
pages = "S13-S14",
doi = "10.1016/S0960-9776(07)70069-3"
}

Nikolić-Vukosavljević, D., Mandušić, V., Nešković-Konstantinović, Z.,& Dimitrijević, B. B.. (2007). Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance. in Breast, 16, S13-S14.
https://doi.org/10.1016/S0960-9776(07)70069-3

Nikolić-Vukosavljević D, Mandušić V, Nešković-Konstantinović Z, Dimitrijević BB. Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance. in Breast. 2007;16:S13-S14.
doi:10.1016/S0960-9776(07)70069-3 .

Nikolić-Vukosavljević, Dragica, Mandušić, Vesna, Nešković-Konstantinović, Zora, Dimitrijević, Bogomir B., "Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance" in Breast, 16 (2007):S13-S14,
https://doi.org/10.1016/S0960-9776(07)70069-3 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Krtolica-Žikić, Koviljka
AU  - Krajnović, Milena M.
AU  - Dimitrijević, Bogomir B.
AU  - Konstantinovic, M.
AU  - Baltić, Vladimir
AU  - Prtenjak, Gordana
AU  - Stojiljković, Bratislav
AU  - Breberina, Milan
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2006
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3079
AB  - Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.
T2  - Clinica Chimica Acta
T1  - Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients
VL  - 371
IS  - 1-2
SP  - 191
EP  - 193
DO  - 10.1016/j.cca.2006.02.027
ER  - 

@article{
author = "Ivanović, Vesna and Demajo, Miroslav and Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Dimitrijević, Bogomir B. and Konstantinovic, M. and Baltić, Vladimir and Prtenjak, Gordana and Stojiljković, Bratislav and Breberina, Milan and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2006",
abstract = "Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.",
journal = "Clinica Chimica Acta",
title = "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients",
volume = "371",
number = "1-2",
pages = "191-193",
doi = "10.1016/j.cca.2006.02.027"
}

Ivanović, V., Demajo, M., Krtolica-Žikić, K., Krajnović, M. M., Dimitrijević, B. B., Konstantinovic, M., Baltić, V., Prtenjak, G., Stojiljković, B., Breberina, M., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2006). Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta, 371(1-2), 191-193.
https://doi.org/10.1016/j.cca.2006.02.027

Ivanović V, Demajo M, Krtolica-Žikić K, Krajnović MM, Dimitrijević BB, Konstantinovic M, Baltić V, Prtenjak G, Stojiljković B, Breberina M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta. 2006;371(1-2):191-193.
doi:10.1016/j.cca.2006.02.027 .

Ivanović, Vesna, Demajo, Miroslav, Krtolica-Žikić, Koviljka, Krajnović, Milena M., Dimitrijević, Bogomir B., Konstantinovic, M., Baltić, Vladimir, Prtenjak, Gordana, Stojiljković, Bratislav, Breberina, Milan, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients" in Clinica Chimica Acta, 371, no. 1-2 (2006):191-193,
https://doi.org/10.1016/j.cca.2006.02.027 . .

TY  - CONF
AU  - Todorović-Raković, N.
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2718
C3  - European Journal of Cancer Supplements / EJC Supplements
T1  - Transforming growth factor-beta1 and steroid receptor status in breast cancer
VL  - 2
IS  - 3
SP  - 105
EP  - 105
DO  - 10.1016/S1359-6349(04)90778-1
ER  - 

@conference{
author = "Todorović-Raković, N. and Ivanović, Vesna and Demajo, Miroslav and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2004",
journal = "European Journal of Cancer Supplements / EJC Supplements",
title = "Transforming growth factor-beta1 and steroid receptor status in breast cancer",
volume = "2",
number = "3",
pages = "105-105",
doi = "10.1016/S1359-6349(04)90778-1"
}

Todorović-Raković, N., Ivanović, V., Demajo, M., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2004). Transforming growth factor-beta1 and steroid receptor status in breast cancer. in European Journal of Cancer Supplements / EJC Supplements, 2(3), 105-105.
https://doi.org/10.1016/S1359-6349(04)90778-1

Todorović-Raković N, Ivanović V, Demajo M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Transforming growth factor-beta1 and steroid receptor status in breast cancer. in European Journal of Cancer Supplements / EJC Supplements. 2004;2(3):105-105.
doi:10.1016/S1359-6349(04)90778-1 .

Todorović-Raković, N., Ivanović, Vesna, Demajo, Miroslav, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Transforming growth factor-beta1 and steroid receptor status in breast cancer" in European Journal of Cancer Supplements / EJC Supplements, 2, no. 3 (2004):105-105,
https://doi.org/10.1016/S1359-6349(04)90778-1 . .